DENVER — The new standard of care, valganciclovir, is inferior to established combination therapy in patients undergoing high-risk orthotopic liver transplantation, a new study suggests. In the ...

For kidney transplant recipients, infection with a virus called cytomegalovirus may lead to devastating complications. New research suggests that extending the period of preventive treatment after ...

Study to evaluate the safety and exploratory efficacy of SYN002 in recipients of human cytomegalovirus (CMV) positive donor kidneys, and to monitor for viral reactivation over the six months following ...

Letermovir is noninferior to valganciclovir for prevention of cytomegalovirus (CMV) among CMV-seronegative kidney transplant recipients who receive an organ from a CMV-seropositive donor, according to ...

Cytomegalovirus (CMV) is a ubiquitous herpesvirus that persists indefinitely after primary infection, usually in a latent form in various tissues (e.g., kidney, liver, lung). [1] One percent of ...

Hematopoietic stem cell transplantation (SCT), being performed with an increasing frequency for a variety of both malignant and non-malignant conditions, is associated with the occurrence of many ...

Letermovir is an investigational once-daily antiviral medicine under development for the prevention of CMV infection and disease. It is a member of a new class of non-nucleoside CMV inhibitors (3,4 ...

Merck & Co’s – known as MSD outside the US and Canada – Prevymis (letermovir) demonstrated non-inferior efficacy and a more favourable safety profile compared to standard of care valganciclovir in a ...

SEATTLE--(BUSINESS WIRE)--Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced that it has dosed the first patient in a Phase 2a clinical trial of ...

Director of Serology and Virology Division (SAViD), Director Organ and Tissue Donor screening laboratory, Director NSW State Reference Laboratory for HIV, Chair Biosecurity Quality Assurance ...

We evaluated HDACV and pre-emptive GCV to prevent CMV disease in pediatric patients following PBSCT. During a period of almost 5 years (from May 1998 to April 2003), 76 pediatric patients with a ...

Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing ...